HUTCHMED DRC

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong, the United States, and internationally. Its products include Fruquintinib for colorectal, breast, gastric, endometrial, lung, and renal cancers, and Savolitinib for non-small cell lung cancer, papillary renal cell carcinoma, and gastric cancer. The company also develops Surufatinib, Sovleplenib, Tazemetostat, Fanregratinib, Ranosidenib, and other drug candidates. It has collaboration agreements with AstraZeneca, Lilly, Takeda, Inmagene, Innovent, and Epizyme. Formerly Hutchison China MediTech Limited, it changed its name to HUTCHMED (China) Limited in May 2021, was incorporated in 2000, and is headquartered in Hong Kong.